Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Exploration of Endocrine and Metabolic Diseases · 2025
DOI: 10.37349/eemd.2025.101452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, 2025. Verfasst von Nino Turashvili. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and dual incretin agonists have demonstrated significant potential in improving adipose tissue function beyond their established effects on appetite suppression and weight loss. These agents not only reduce overall fat mass but also induce favorable changes in fat distribution and adipose tissue quality. Notably, they enhance brown adipose tissue (BAT) activity and promote the browning of white adipose tissue (WAT), thereby increasing energy expenditure. They are associated with reductions in adipocyte size, particularly within visceral fat depots, alongside improvements in metabolic health markers. The aim of this publication is to provide a literature review on the effects of GLP-1RAs and dual incretin agonists on adipocyte type and size, adipose tissue functional remodeling, and their implications for obesity management. These findings highlight the capacity of incretin-based therapies to modulate adipose tissue biology, offering metabolic benefits that extend beyond weight reduction.
Zitieren
APA
Turashvili, N. (2025). Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size. Exploration of Endocrine and Metabolic Diseases. https://doi.org/10.37349/eemd.2025.101452
Vancouver
Turashvili N. Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size. Exploration of Endocrine and Metabolic Diseases. 2025. doi:10.37349/eemd.2025.101452
BibTeX
@article{Turashvili2025,
author = {Turashvili, Nino},
title = {Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size},
journal = {Exploration of Endocrine and Metabolic Diseases},
year = {2025},
doi = {10.37349/eemd.2025.101452}
}
EUVIMED